NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 2706Y 
Neuropharm Group PLC 
01 September 2009 
 

+------------------------------------------+------------------------------------+ 
| For immediate release                    |                   1 September 2009 | 
+------------------------------------------+------------------------------------+ 
 
 
 
 
 
 
Neuropharm Group plc 
("Neuropharm" or "the Company") 
 
 
Notice of Preliminary Results 
 
 
 
 
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on 
neurodevelopmental disorders, will announce its preliminary results for the year 
ended 30 June 2009 on Wednesday 30 September 2009. 
 
 
 
 
 
 
 
 
For further information please contact: 
 
 
+-----------------------------------------------+--------------------+ 
| Neuropharm                                    |  + 44 (0) 1372 371 | 
|                                               |                171 | 
+-----------------------------------------------+--------------------+ 
| Robert Mansfield, Chief Executive Officer     |                    | 
| Graham Yeatman, Chief Financial Officer       |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Piper Jaffray Ltd.                            |   + 44 (0) 20 3142 | 
|                                               |               8700 | 
+-----------------------------------------------+--------------------+ 
| Neil Mackison, Rupert Winckler                |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Buchanan Communications                       |   + 44 (0) 20 7466 | 
|                                               |               5000 | 
+-----------------------------------------------+--------------------+ 
| Mark Court, Mary-Jane Elliot, Catherine Breen |                    | 
+-----------------------------------------------+--------------------+ 
 
 
Notes to Editors: 
 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NORFGGFRMMLGLZZ 
 

Neuropharm (LSE:NPH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Neuropharm (LSE:NPH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024